Leader in Biomolecular Solutions for Life Science

www.abclonal.com

SARS-CoV-2 neutralizing antibody

Catalog No.: A19215 **8 Publications**

Basic Information

Observed MW
Refer to figures

Calculated MW

Category
Primary antibody

Applications
< 0.1 EU/μg of the protein by LAL method.

Cross-Reactivity

CloneNo number
AHC0005

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection caused COVID-19. This response focuses on the mechanism by which SARS-CoV-2 enters host cells, specifically the binding of the spike(S) protein to its receptor angiotensin-converting enzyme 2 (ACE2) and subsequent membrane fusion. SARS-CoV-2 neutralizing antibodies have been developed for preventive or therapeutic uses. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein1-5 show promise therapeutically .Neutralizing antibodies can block infection, clear pathogens, and are essential to provide long-term immunity. While neutralizing antibodies target the spike protein, their neutralization potency and breadth vary according to recognition epitopes.

Recommended Dilutions

Lyophilized from a 0.22 μm filtered solution of PBS pH 7.2

Immunogen Information

Gene ID **Swiss Prot**

Immunogen
Recombinant protein (or fragment).This information is considered to be commercially sensitive.

Synonyms

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

Product Information

Source
SARS-CoV-2

Isotype
Human IgG1/kappa

Purification
>95% as determined by SDS-PAGE

Storage
Store at -20℃